Clinical trial NCT01202617: Seroquel XR in the Long Term Treatment of Schizophrenia
Official title: Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Relapse in Schizophrenia
Keywords: Seroquel XR
schizophrenia
relapse prevention
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-09-16
Enrollment: 1606
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Psychiatric outpatients

Brief summary: The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients


Eligibility criteria: Inclusion Criteria:

* schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

* Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Primary outcomes:
measure: Rate of patients remained relapse free after 6 months of treatment
timeFrame: on the 60th day of treatment
measure: Rate of patients remained relapse free after 6 months of treatment
timeFrame: on the 180th day of treatment
Secondary outcomes:
measure: connection between relapse and affective symptoms
timeFrame: on the 60th day of treatment
measure: connection between relapse and affective symptoms
timeFrame: 180th day of treatment
Other outcomes:
Locations:
city: Baja
country: Hungary
facility: Research Site
city: Balassagyarmat
country: Hungary
facility: Research Site
city: Barcs
country: Hungary
facility: Research Site
city: Berettyoujfalu
country: Hungary
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Cegled
country: Hungary
facility: Research Site
city: Csongrad
country: Hungary
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Dombovar
country: Hungary
facility: Research Site
city: Dunaujvaros
country: Hungary
facility: Research Site
city: Eger
country: Hungary
facility: Research Site
city: Emod
country: Hungary
facility: Research Site
city: ERD
country: Hungary
facility: Research Site
city: Esztergom
country: Hungary
facility: Research Site
city: Godollo
country: Hungary
facility: Research Site
city: Gyongyos
country: Hungary
facility: Research Site
city: Gyor
country: Hungary
facility: Research Site
city: Gyula
country: Hungary
facility: Research Site
city: Hajdusamson-Martinka
country: Hungary
facility: Research Site
city: Hajduszoboszlo
country: Hungary
facility: Research Site
city: Heves
country: Hungary
facility: Research Site
city: Janoshalma
country: Hungary
facility: Research Site
city: Jaszbereny
country: Hungary
facility: Research Site
city: Kalocsa
country: Hungary
facility: Research Site
city: Karcag
country: Hungary
facility: Research Site
city: Kecskemet
country: Hungary
facility: Research Site
city: Kerepestarcsa
country: Hungary
facility: Research Site
city: Ketegyhaza
country: Hungary
facility: Research Site
city: Kiskunhalas
country: Hungary
facility: Research Site
city: Kiskunmajsa
country: Hungary
facility: Research Site
city: Kistokaj
country: Hungary
facility: Research Site
city: Komarom
country: Hungary
facility: Research Site
city: Kozarmisleny
country: Hungary
facility: Research Site
city: Miskolc
country: Hungary
facility: Research Site
city: Nagyatad
country: Hungary
facility: Research Site
city: Nagykallo
country: Hungary
facility: Research Site
city: Nagykanizsa
country: Hungary
facility: Research Site
city: Nagykoros
country: Hungary
facility: Research Site
city: Ny�regyhaza
country: Hungary
facility: Research Site
city: Pecs
country: Hungary
facility: Research Site
city: Pomaz
country: Hungary
facility: Research Site
city: Salgotarjan
country: Hungary
facility: Research Site
city: Satoraljaujhely
country: Hungary
facility: Research Site
city: Soltvadkert
country: Hungary
facility: Research Site
city: Sopron
country: Hungary
facility: Research Site
city: Szeged
country: Hungary
facility: Research Site
city: Szeghalom
country: Hungary
facility: Research Site
city: Szekesfehervar
country: Hungary
facility: Research Site
city: Szekszard
country: Hungary
facility: Research Site
city: Szentendre
country: Hungary
facility: Research Site
city: Szentes
country: Hungary
facility: Research Site
city: Szigetszentmiklos
country: Hungary
facility: Research Site
city: Szigetvar
country: Hungary
facility: Research Site
city: Szolnok
country: Hungary
facility: Research Site
city: Szombathely
country: Hungary
facility: Research Site
city: Tatabanya
country: Hungary
facility: Research Site
city: Tata
country: Hungary
facility: Research Site
city: Toszeg
country: Hungary
facility: Research Site
city: Vac
country: Hungary
facility: Research Site
city: Veszprem
country: Hungary
facility: Research Site
city: Zalegerszeg
country: Hungary
facility: Research Site
Study officials:
affiliation: National Psychiatric Centre
name: Attila Nemeth
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca
name: Lilla Szabo
role: STUDY_CHAIR
affiliation: AstraZeneca
name: Alexandra Henringh
role: STUDY_DIRECTOR
References: